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Diabetic polyneuropathy (DPN) is the most common complication that emerges early in
diabetic patients. Intervention with strict blood glucose control or treatment with aldose
reductase inhibitor is reported to be effective in early stages of DPN. Curative treatment
for overt or symptomatic DPN, however, has not been established, thus requiring much
effort to explore a new therapy. Recent preclinical studies on the use of gene or cell therapy
have provided promising results in the treatment of DPN. Of particular interest, induced
pluripotent stem cells are introduced. In these studies, restoration of DPN was proposed
to be attributed to either neurotrophic factors released from transplanted stem cells or
differentiation of stem cells to substitute the damaged peripheral nerve.There are still sev-
eral problems, however, that remain to be overcome, such as perturbed function, fragility,
or limited survival of transplanted cells in diabetes milieu and risk for malignant transfor-
mation of transplanted cells. Questions, which cell is the most appropriate as the source
for cell therapy, or which site is the best for transplantation to obtain the most effective
results, remain to be answered. In this communication, we overview the current status of
preclinical studies on the cell therapy for DPN and discuss the future prospect.
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INTRODUCTION
Diabetic polyneuropathy (DPN) is an early and frequent com-
plication of diabetes. Before symptoms become evident, most
diabetic patients exhibit more or less abnormal peripheral nerve
function such as prolonged F wave latency or reduced nerve con-
duction velocity of sural and tibial nerves, indicative of early
metabolic interference to nerve integrity (1). Population of small
fibers in the skin observed by confocal laser scan microscopy is
also found to be dramatically reduced in patients with impaired
glucose tolerance, pre-diabetic stage of type 2 diabetic patients
(2). It is thus likely that there is almost no patient who does not
suffer from incipient progression of nerve damage in the pres-
ence of diabetes. Current consensus on the diagnosis of DPN
depends on clinical and/or electrophysiological abnormalities in
peripheral nerve after exclusion of the causes other than diabetes.
Distal dominant polyneuropathy is the most frequent type of dia-
betic neuropathy, and further divided into symmetric sensory
dominant neuropathy and autonomic neuropathy. Underlying
pathology of diabetic neuropathy is characterized by a progres-
sive distal axonal degeneration, axonal loss, and demyelination (3,
4) accompanied by microvascular changes, which exhibit typical
features of microangiopathy with thickening of basement mem-
brane and luminal occlusion (5–7). Under such circumstances,
peripheral nerve tissues undergo ischemia and poor supply of
nerve nutrients as well as nerve trophic factors, thus contribut-
ing to development of neuropathy. In addition, local depletion
of neurotrophic factors such as nerve growth factor (NGF),
insulin-like growth factor (IGF)-I, and vascular endothelial growth
factor (VEGF) may attribute to the distal pre-dominant nerve
pathology.
Patients with such pathology complain intractable pain, insom-
nia, and depression. In advanced stage, contracted foot may be
amputated in the absence of perception by the reason for non-
curable diabetic gangrene and local infection. Thus, the neuropa-
thy impairs quality of life, resulting in premature death of the
patients.
While a number of reports disclosed that intervention with
tight blood glucose control, treatment with aldose reductase
inhibitor or alpha-lipoic acid successfully suppressed the pro-
gression of neuropathy (8–10), there is no established curable
treatment in progressive stage. Notwithstanding, there have been
continuous efforts to develop new means to combat with this seri-
ous disorder. One of innovative preclinical studies may be depicted
as application of gene therapy or cell therapy to experimental dia-
betic neuropathy in animal models (11). Among those, there are
several reports that exhibited promising results. As a source of
cell therapy, embryonic stem cell (ES cell), inducible pleuriopo-
tent stem cell (iPS cell), bone marrow-derived mononuclear cell
(BMMNC), mesenchymal stem cells (MSC), and others as well
may be listed (Table 1). ES cell is excluded in this group because
of the ethical problems and a risk of tumor formation. We will
discuss in this communication on the effects of endothelial prog-
enitor cells, MSC, and induced pluripotent stem (iPS) cells on
experimental diabetic neuropathy.
ENDOTHELIAL PROGENITOR CELLS
Naruse et al. examined the effects of cord blood-derived endothe-
lial progenitor cells (CB-EPC) on neuropathic changes in strep-
tozotocin (STZ)-induced diabetic rats (12). In this study, 1× 106
number of CB-EPC were transplanted into quadriceps muscle,
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Table 1 | Source of cell therapy for experimental diabetic neuropathy.
Name of stem cells Advantages Weak points
Cord blood-derived endothelial progenitor cell
(CB-EPC) (12)
Efficient utilization of cords that is unused No application to autologous
transplantation
Bone marrow-derived endothelial progenitor cells
(BM-EPC) (13)
Transdifferentiation into local intrinsic
endothelial cells
Ex vivo expansion
Functional loss in diabetes
Peripheral blood mononuclear cell (PBMNC) (14) Low invasiveness Functional loss in diabetes
Application to autologous transplantation
Bone marrow mononuclear cell (BMMNC) (14–16) Application to autologous transplantation Functional loss in diabetes
Inducible pluripotent stem cells (iPSC) (17) Utilization of adult somatic cells Gene introduction using virus vector
Tumor formation
Bone marrow-derived mesenchymal stem cell
(BMMSC) (18–20)
Low invasiveness Ex vivo expansion
Tumor formation
Functional loss in diabetes
Short effective period
Adipose tissue-derived mesenchymal stem cell (ASC) Low invasiveness Short effective period
No ex vivo expansion Functional loss in diabetes
biceps femoris muscle, and soleus muscle in nude rats with 8-
week diabetic duration. Four weeks after transplantation, treated
group showed improvement of motor nerve conduction velocity
(MNCV) and sciatic nerve blood flow (SNBF) only in transplanted
limb compared to non-treated side. They interpreted that the
recovery of nerve function was accounted for by improved SNBF
related to increased vascular density in the treated leg muscles.
Jeong et al. applied bone marrow-derived endothelial progenitor
cells (BM-EPC) to neuropathy in STZ-induced diabetic mice (13).
BM-EPC transplantation improved not only MNCV and SNBF,
but also increased the density of vasa nervorum in the sciatic nerve.
To our surprise, transplanted BM-EPC migrated along the vessel
wall of sciatic nerve and fused with endothelial cells, intrinsic to
the host mouse. Upregulated expression of mRNA or proteins
of VEGF, basic fibroblast growth factor (bFGF), brain-derived
neurotrophic factor (BDNF), and stromal cell-derived factor 1a
was also demonstrated in the sciatic nerve. From these results,
it is likely that EPC transplantation is beneficial for treatment
of diabetic neuropathy thorough augmented expression of neu-
rotrophic factors and improvement of vascular function perhaps
based on increased blood vessels in part associated with newly built
endothelial cells derived from EPC. It is yet to be clear, however, in
these studies, to which extent transplanted cells survive or to what
transplanted cells differentiate into. Longer observation should be
essential to answer to this question.
PERIPHERAL BLOOD MONONUCLEAR CELL AND BONE
MARROWMONONUCLEAR CELL
Mononuclear cells which contain various kinds of cell lineages,
such as hematopoietic cells, fibroblasts, osteoblasts, and myogenic
cells as well as endothelial lineage, can work beneficially in var-
ious settings (21). The effects of peripheral blood mononuclear
cell (PBMNC) and BMMNC on neuropathy in STZ-induced dia-
betic rats were examined by Hasegawa et al. (14). After 4 weeks
of diabetes, 6× 107 PBMNC or 1× 106 BMMNC were trans-
planted into the hindlimb muscle. Four weeks after transplan-
tation, both MNCV and SNBF on transplanted limb were signif-
icantly improved while those in non-transplanted limb remained
low. The effects of either PBMNC or BMMNC were set off when
neutralizing antibody to VEGF was pre-treated. From these results,
the therapeutic effects of PBMNC and BMMNC may mainly
be attributed to the improvement of VEGF-mediated vascular
function, and share common with the effects of EPC. In con-
trast to EPC, however, microvascular density in the sciatic nerve
was not influenced by MNC therapy. More recent study con-
ducted by Kim et al. demonstrated robust improvement of neu-
ropathy in STZ-induced diabetic rats transplanted with 5× 105
BMMNC along the sciatic nerve (15). Indeed, transplantation of
BMMNC ameliorated MNCV, sensory nerve conduction veloc-
ity (SNCV), and SNBF as well as perineurial microvessel density
around the sciatic nerve. They further found migration of trans-
planted BMMNC into the sciatic nerve along the endoneurial
vessels although no obvious fusion of MNC with endothelial
cells was identified. Concurrently, mRNA expression of neu-
rotrophic factors such as VEGF, bFGF, IGF-I, and nitric oxide
synthase-3 in transplanted site was significantly restored com-
pared to the other site. More recently, a study conducted by
Naruse et al. showed improvement of hyperalgesia and mechan-
ical allodynia in STZ-induced diabetic rats transplanted with
autologous BMMNC into gastrocunemius muscle (16). They
assumed that the local recovery of microcirculation in the mus-
cle was the main cause for the therapeutic efficacy of autolo-
gous BMMC. Intriguingly, but requiring caution for the inter-
pretation, intraepidermal nerve fiber density (IENFD) was not
affected in their study. It is thus likely that MNC ameliorates neu-
ropathy mainly mediated by vascular function, but it remains
unclear whether the functional recovery links with structural
repair.
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INDUCED PLURIPOTENT STEM CELL
Induced pluripotent stem cells are stem cells induced artificially
from mature somatic cells by insertion of four genes (oct3/4, sox2,
klf4, c-myc) using a vector of retrovirus (22). There is a possi-
bility of tumor formation from iPS cells because c-myc is one
of the potent oncogenes. Recently, L-myc or glis-1 is alternatively
applied to the induction of iPS cells as being safer than c-myc
(23, 24). Moreover, three candidate genes were identified as non-
tumorigenic iPS cell (25). According to the efforts to improve the
quality of iPS cells, transplantation therapy of iPS cells is expected
to be safer than before.
There is one publication that introduced beneficial effects of iPS
cells on experimental diabetic neuropathy (17). The authors pro-
duced iPS cells from aged mouse to develop into neural crest cells,
which in turn possessed a potency to differentiate into the con-
stituents of peripheral nerve tissues including neurons, Schwann
cells and vascular smooth muscle cells. The differentiated iPS cells
were transplanted into hindlimb of STZ-induced diabetic mice
with 16-week diabetic duration. Four weeks after transplanta-
tion, NCVs, nerve population in the footpad (IENFD), perception
impairments to thermal stimuli were significantly improved. In
these animals, the improvement of neuropathic changes was asso-
ciated with recovery of sciatic nerve and plantar skin blood flow
and increased capillary density in the muscle. They further found
increased protein expressions of neurotrophic factors such as
NGF and VEGF only in the sciatic nerve, but not in the DRG.
It was thus indicated that the effects of transplanted cells were
only local not to the distant tissues. In this study, the investiga-
tors exhibited the illustrations of differentiation of implanted iPS
cells to vascular smooth muscle cells or Schwann cell-like cells in
each counterpart of the recipients. Nevertheless, the mechanism
of how iPS therapy influenced on neuropathy may be more or
less similar to those in other kinds of stem cell therapy, which
induces or enhances local release of neurotrophic factors. Several
questions still remain as to how long the implanted cells can sur-
vive at the local site, or to which extent there is a risk for the
tumor formation. If we can overcome these obstacles, iPS cell
therapy could be the most promising for the advanced stage of
neuropathy because ample amount of iPS cells will be available
for transplantation by its easy procurement from mature somatic
cells.
MESENCHYMAL STEM CELL
Mesenchymal stem cells are a group of stem cells, which are con-
tained in various adult tissues including bone marrow, adipose
tissue, and spinal ligaments (26–28). These cells express CD44,
CD90, or CD105 as surface markers. Two kinds of MSC are
representative; one purified from bone marrow (bone marrow-
derived MSC; BMSC) and another from adipose tissue (adipose
tissue-derived MSC: ASC). Since ASC seems to be migrated BMSC
into the adipose tissue, there is no marked phenotypic difference
between ASC and BMSC (29, 30). It is of note that pericytes that
surround small capillaries express cell surface phenotype (CD44,
CD90, and CD105) similar to those possessed by MSC that has
multipotential differentiation into bone or cartilage. Thus, a part
of pericytes are considered to be a precursor of MSC (31). In
fact, the infusion of MSC into blood vessels in vivo resulted in
localization of MSC surrounding vessels that differentiated into
pericyte (31).
Several reports disclosed the effects of MSC therapy on exper-
imental diabetic neuropathy. Shibata et al. transplanted 1× 106
BMSC into femoral and gastrocunemius muscle of STZ-induced
diabetic rats with 8 weeks duration (18). BMSC transplantation
significantly improved MNCV, SNBF and increased density of
small vessels in the muscle in the transplanted limbs 4 weeks
after the transplantation. They found increased mRNA expres-
sions of VEGF and bFGF, and neurofilament protein expression
in the transplanted site. Myelinated fiber morphometry revealed
restored axonal circularity in BMSC-implanted limb of diabetic
rats, but no changes in myelin area in those animals suggest-
ing limited effects on myelination. Kim et al. also transplanted
1× 106 BMSC in the muscles along the sciatic nerve in STZ-
induced diabetic mice with 12-week diabetic duration (19). Two
weeks later, they found significant improvement of mRNA expres-
sion of neurotrophic factors such as NT-3 and NGF. Contrary to
the expectation, however, the effects of BMSC diminished 4 weeks
after the transplantation. From the above two reports, the effective
period of the BMSC transplantation therapy was found to be only
2–4 weeks after transplantation regardless of the animal species or
duration of diabetes. In their studies, not autologous, but allogenic
BMSC was used for transplantation. Thus, the dwindling of the
efficacy in transplanted animals may be ascribed to the removal
of the cells by the immune system of recipient. The limitation of
allogenic MSC therapy may also be related to the gradual decrease
in released neurotrophic factors from transplanted cells that may
sustain only 4 weeks or so after transplantation. Another issue that
should be overcome for the MSC therapy is to avoid the risk of
tumor formation. In fact, Jeong et al. found frequent tumor for-
mation in STZ-induced diabetic mice transplanted with BMSC
(20). In this study, 4–8 weeks after the transplantation, sarcoma
with muscle phenotype was identified in the transplanted site in
46% of treated animals. The high frequency of tumor formation
was accounted for by frequent chromosomal mutation elicited by
repeated passages of BMSC (only four passages) in the cell culture
system. It may thus be conceivable that fresh BMSC without any
passage in cell culture should be applied to cell therapy to prevent
tumor formation.
ADVANTAGE OF ASC IN CLINICAL APPLICATION
Adipose tissue-derived mesenchymal stem cell has unique advan-
tage over the other kinds of MSC that do not have, represented
by the fact that, (1) less invasive procedure is required for its iso-
lation, (2) ASC locates in mature adipose tissue, (3) there is no
need for ex vivo culture after isolation, (4) automatic cell sorter
is available on the market (29, 32), and (5) ASC is less immuno-
genic. By the reason of (1–5), autologous cell transplantation of
ASC is feasible as a source of cell therapy. In case of BMSC, ex
vivo culture is indispensable because the volume of bone mar-
row blood available for one time is restricted. Litter of the fatty
tissue is allowed to collect by lipoaspiration technique, enabling
primarily isolated ASC for transplantation. As mentioned in the
previous section, there is a risk that ex vivo culture may cause
chromosomal abnormality of MSC. Thus, ASC seems to be supe-
rior for clinical application compared to other kinds of MSC.
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FIGURE 1 | Mechanism of the effect of stem cell transplantation on
diabetic neuropathy. The mechanism of nerve repair by stem cell
transplantation may be divided into two main pathways. One is the
enhancement of local expression of neurotrophic factors and another is the
cell engraftment and differentiation into tissue constituents of large tissues.
Most stem cells can improve the local expression of neurotrophic factors, but
from the literature only two kinds of stem cells (bone marrow-derived
endothelial progenitor cells and iPS cell) were found to achieve cell
engraftment and differentiation in the target tissues. Collectively, stem cells
can improve motor and sensory nerve conduction velocity (MNCV and SNCV),
sciatic nerve blood flow (SNBF), capillary density, intraepidermal nerve fiber
density (IENFD), hyperalgesia, and mechanical allodynia.
Indeed, ASC is already clinically applied to cardiovascular dis-
eases like acute myocardial infarction, wound healing of skin ulcer,
or plastic surgery such as mammoplasty as well as facial repair.
Good news is that safety of the ASC therapy has already been
confirmed (33).
MECHANISM OF TISSUE REPAIR IN ASC THERAPY
Adipose tissue-derived mesenchymal stem cell can induce tis-
sue repair through several potential mechanisms mediated by (1)
neurotrophic factors released from transplanted ASCs, (2) dif-
ferentiation and engraftment of ASCs in the target organs, (3)
immunosuppressive effects of ASCs. It may be conceivable that the
effects of ASCs are largely based on released neurotrophic factors.
ASCs produce a variety of neurotrophic factors such as epider-
mal growth factor, transforming growth factor-β, VEGF, bFGF,
hepatocyte growth factor, IGF-I, and BDNF. Of these factors, the
expression of VEGF, bFGF, IGF-I, and BDNF was shown to be
decreased in peripheral nerve tissues of experimental diabetic neu-
ropathy. ASCs transplantation can restore the expression of these
neurotrophic factors, which in turn ameliorates neuropathy. The
underlying process may be similar to the substitution of these
neurotrophic factors. As already alluded, most transplanted stem
cells cannot survive in transplanted site for a long time (less than
1 month). It may therefore be difficult to expect differentiation
and engraftment of ASCs in transplanted site like other stem cells.
Immunosuppressive effect of ASC may also be expected by the
recent experimental findings, which showed suppressive effects of
ASCs on inflammatory reactions in the animal models of fulmi-
nant hepatitis, ulcerative colitis, and Crohn’s disease (34, 35). Since
inflammatory processes contribute to the development of diabetic
neuropathy, the effects of ASC may in part be ascribed to the coun-
teraction against proinflammatory reactions. However, this issue
should be confirmed by future investigations.
In our own experience, we found significant recovery of nerve
conduction delay in STZ-induced diabetic rats 2 weeks after ASC
transplantation. Concurrently, the atrophy of the ganglion cells in
DRG was improved. mRNA expression of the neurotrophic fac-
tors such as VEGF in soleus muscle at the transplanted site was
increased while contralateral limb was not affected. Histological
evaluation could not identify differentiation of ASC to either neu-
ronal cells or Schwann cells, nor increase in capillary density in
the muscles 4 weeks after the transplantation. Summarizing these
results, ASC can improve the peripheral nerve function in dia-
betic neuropathy through the increase in the local expression of
neurotrophic factors.
EFFECTS OF STEM CELLS ON DIABETIC SKIN ULCER
Diabetic foot ulcer is common but serious complications of dia-
betes frequently associated with DPN and suitable target for cell
therapy. Previous reports exhibiting the effectiveness of diversity
of stem cells including MSC, EPC, and previous literature disclosed
the beneficial effects of BM–BMMC on the wound repair in exper-
imental diabetic animal model (36). The mechanisms that operate
in those models are more or less similar to those alluded in the case
of the DPN involving replenishment of growth factor production,
suppression of the sustained inflammation, and improvement of
blood supply by neovascularization. Small population of trans-
planted stem cells could differentiate into endothelial cells in
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transplanted sites. It is less likely, however, that this mechanism
in fact is a major process for the recovery because of a paucity of
such differentiated cells.
DIABETES AND STEM CELL DYSFUNCTION
Hyperglycemic state may affect stem cell function. There are sev-
eral publications that showed functional impairment of MSCs,
EPC, and BMMC (37–39). They underwent reduced proliferative
activity (38), impaired fibrinolytic activity (40), poor differen-
tiation into endothelial cells or osteocytes (41), but untoward
differentiation into adipocyte (42), and induction of apoptosis
(38). EPC procured from diabetic patients suffers from low yield
dependent on high HbA1c and low proliferation activity with
impaired tubule formation (43, 44). The dysfunction of EPC was
proposed to be relevant to insulin resistance, cellular senescence,
or other glucose-dependent cell damage like advanced glycation
end products (AGE) formation as well as alterations of its receptor
(RAGE) (38, 41, 45).
FUTURE PERSPECTIVE OF CELL THERAPY
As shown in Figure 1, stem cells can improve diabetic neuropa-
thy through two main pathways. One is the enhancement of
the expression of local neurotrophic factors, and another is the
engraftment and differentiation into tissue constituents in tar-
get tissues (Figure 1). Cell therapy may be applicable not only
to acute serious illnesses like myocardial infarction, but also to
chronic disorders represented by diabetic neuropathy. There is
a great expectation of the development of cell therapy effective
for advanced stage of neuropathy or severe painful neuropathy in
diabetes because we lack effective treatment except for palliative
observation of the patients.
Despite numerous promising results from hitherto published
preclinical studies, there appear to be many obstacles to be over-
come for clinical applications. Those are: (1) limited survival of
transplanted cells, (2) risk of tumor formation, (3) cost and effect
relationship, (4) undetermined site of transplantation for safety
and effectiveness, (5) choice of the most suitable stem cells tailored
for a given patient, (6) impaired potency of stem cells derived from
diabetic patients, and finally (7) unestablished clinical endpoints
for the efficacy of cell therapy. Thus, much more information is
needed before considering clinical application.
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